FortuneStar S&T

FortuneStar S&T is a specialized research and development subsidiary of Fosun Pharma, focused on the discovery and clinical development of innovative small molecule therapeutics. The company manages a diverse pipeline of targeted therapies, primarily in the field of oncology, including MEK inhibitors, BCL-2 inhibitors, and TRK inhibitors. Operating as an integral part of Fosun Pharma's global R&D network, FortuneStar S&T oversees early-to-late-stage clinical trials and intellectual property management for the group's proprietary drug candidates. Its lead programs target high-unmet-need conditions such as neurofibromatosis type 1 and various hematological cancers.